VativoRx cited as a Top 10 PBM solutions provider

For years, Medicare drug price negotiation was mostly discussed as a Part D story. That changed in January, when CMS selected 15 drugs for the third cycle of negotiation, including the first drugs payable under Medicare Part B. Negotiations take place in 2026, and any negotiated prices from this cycle take effect in 2028.

What the Consolidated Appropriations Act of 2026 May Mean for Health Plans and Pharmacy Benefit Oversight

CMS has placed renewed emphasis on payment accuracy in Medicare Advantage (MA). While the headlines often focus on how plans are paid, provider organizations should focus on what typically follows: shifts in utilization management posture, contracting dynamics, and documentation sensitivity.

TrumpRx.gov has quickly become part of the national conversation on prescription affordability. For provider organizations, the value in tracking TrumpRx isn’t political; it’s operational. Programs like this can influence patient expectations, pricing conversations at the point of care, and the way stakeholders interpret “drug cost” when list, net, and out-of-pocket prices don’t align.